2seventy bio, Inc. financial data

Symbol
TSVT on Nasdaq
Industry
Pharmaceutical Preparations
Location
60 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 423 % -5.29%
Debt-to-equity 127 % +29.1%
Return On Equity -40.9 % +23%
Return On Assets -18 % +32.7%
Operating Margin -333 % -137%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.6M shares +1.9%
Common Stock, Shares, Outstanding 51.5M shares +1.77%
Entity Public Float 508M USD +2.34%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 52.3M shares +2.12%
Weighted Average Number of Shares Outstanding, Diluted 52.3M shares +2.12%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 45.6M USD -68.7%
Research and Development Expense 119M USD -50.2%
Costs and Expenses 198M USD -43.6%
Operating Income (Loss) -152M USD +25.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -94.5M USD +48.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -94.5M USD +48.6%
Earnings Per Share, Basic -1.83 USD/shares +47.1%
Earnings Per Share, Diluted -1.86 USD/shares +46.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60M USD -33.5%
Marketable Securities, Current 195M USD +45%
Assets, Current 218M USD -21.2%
Property, Plant and Equipment, Net 35.2M USD -41.9%
Operating Lease, Right-of-Use Asset 206M USD -8.39%
Intangible Assets, Net (Excluding Goodwill) 6.06M USD -10.5%
Goodwill 0 USD -100%
Assets 504M USD -21.4%
Accounts Payable, Current 5.08M USD -4.35%
Employee-related Liabilities, Current 6.59M USD -56.7%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 44.1M USD -35.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 232M USD -6.55%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 276M USD -17.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 305K USD
Retained Earnings (Accumulated Deficit) -549M USD -20.8%
Stockholders' Equity Attributable to Parent 228M USD -25.6%
Liabilities and Equity 504M USD -21.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.9M USD +14.7%
Net Cash Provided by (Used in) Financing Activities 386K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 21.8M USD -51.3%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 51.5M shares +1.77%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -19.7M USD -116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.3M USD -34.5%
Deferred Tax Assets, Valuation Allowance 181M USD +41.2%
Deferred Tax Assets, Gross 249M USD +23.1%
Operating Lease, Liability 257M USD -5%
Payments to Acquire Property, Plant, and Equipment 612K USD -89.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.3M USD +48.4%
Lessee, Operating Lease, Liability, to be Paid 341M USD -7.54%
Property, Plant and Equipment, Gross 63.8M USD -44.4%
Operating Lease, Liability, Current 15.8M USD +28.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 29.5M USD +2.88%
Lessee, Operating Lease, Liability, to be Paid, Year One 28.7M USD +2.91%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 84.8M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 32.9M USD +11.6%
Deferred Tax Assets, Operating Loss Carryforwards 38.7M USD +42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.8M USD +140%
Lessee, Operating Lease, Liability, to be Paid, Year Four 35.1M USD +6.58%
Additional Paid in Capital 777M USD +1.97%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.11M USD -6.56%
Share-based Payment Arrangement, Expense 14.7M USD -59.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%